Thrombosis cases are more frequent after the application of the AstraZeneca anti-covid vaccine than the Pfizer/BioNTech immunizer, although cases are very rare, says a study published this Thursday (27, Wednesday night in Brasilia).
“After a first dose [da vacina AstraZeneca]there is a 30% higher risk of thrombocytopenia compared to a first dose [da vacina da Pfizer/BioNTech]”, notes the large-scale study published by the British Medical Journal (BMJ).
Thrombocytopenia is a form of thrombosis, ie the formation of a blood clot with potentially fatal consequences.
After the launch of vaccination campaigns against Covid-19 since 2021, a link between adenoviral vector vaccines – AstraZeneca and Johnson & Johnson – and the emergence of these blood problems was quickly suspected.
The study, carried out using health data from millions of patients in several countries in Europe and the United States, confirms that these thromboses are more frequent after the AstraZeneca vaccine, but even so, they are very rare: 862 cases for more than one million vaccinated.
The risk appears to increase after the first dose. After the second, there is no difference between the AstraZeneca and Pfizer/BioNTech vaccines.
As for the Johnson & Johnson vaccine, the data indicate a greater risk, but not in a clear enough way for the researchers to draw conclusions.
The study essentially confirms “that all vaccines [anticovid] are safe and effective,” microbiologist Sarah Pitt told AFP, highlighting the “extremely rare” frequency of thrombocytopenia cases.
I have over 3 years of experience working in the news industry. I have worked for various news websites and have been an author at News Bulletin 247 for the past 2 years. I mostly cover technology news and have a keen interest in keeping up with the latest trends in the industry. I am a highly motivated individual who is always looking to improve my skills and knowledge.
